In gratitude of the loyal support of our members, the CNS is offering complimentary 2021 Annual Meeting registration to all members! Learn more.

  • A Phase II Study of Intratumoral Radioimmunotherapy Treatment of Recurrent Glioblastoma Multiforme (GBM) and Review of Current Treatments of Recurrent Glioblastoma Multiform.

    Final Number:
    503

    Authors:
    Deepak Kumar Gupta PhD

    Study Design:
    Clinical Trial

    Subject Category:

    Meeting: Congress of Neurological Surgeons 2013 Annual Meeting

    Introduction: Glioblastoma multiforme (GBM) is the most common /clinically aggressive of primary brain tumors. Prolongation of survival for recurrent GBM has not been convincingly demonstrated with any treatment strategy. 131I-chTNT-1/B MAb is a radioiodinated chimeric monoclonal antibody specific for DNA and histone H1 complex exposed in necrotic core of malignant gliomas.

    Methods: Phase II, open-label, dose confirmatory study. Patients aged 18 to 75 years with histologically confirmed GBM at first relapse, clinical target volume (CTV) of 5 to 60 cc, and Karnofsky Performance Status =70% were eligible. Drug adminstered by convection enhanced delivery via 2 catheters placed under stereotactic guidance, at a constant rate of 0.18 mL/h for 25 hours at dose of 2.5 mCi/cc of CTV. Additional endpoints included overall survival (OS), progression free survival (PFS), and proportion of patients alive at 6 months

    Results: 41 cases were enrolled and received study drug. Mean age was 52 years (24-74). Median CTV was 28.3 cc (1.6-65.8) and median KPS was 80 (70-100). The median administered therapeutic dose was 66.9 mCi (3.5 to 148) with most patients receiving >90% of planned therapy dose. The most common overall adverse events (AEs) (> 10%) were: brain edema (32%), headache (22%), convulsions (20%) and amnesia (12%).Interim median OS currently at 38 weeks and median PFS at 23 weeks

    Conclusions: Single interstitial administration of study drug at 2.5 mCi/cc was well-tolerated in this study of patients with recurrent GBM. Follow-up is continuing, current median survival of 38 weeks is encouraging and further clinical development is warranted.

    Patient Care: Phase II data shows promising outcome data of Glioblastoma multiforme patients

    Learning Objectives: This phase II study shows promising data results from this novel radioimmunotherapeutic compound in treatment of recurrent high grade gliomas.

    References:

We use cookies to improve the performance of our site, to analyze the traffic to our site, and to personalize your experience of the site. You can control cookies through your browser settings. Please find more information on the cookies used on our site. Privacy Policy